Therefore, enhancing the potential of myeloid cells in TME to phagocytose tumor cells by inducing TREM2-mediated phagocytosis could be a potential immunotherapeutic strategy for the treatment of brain tumors. The gene discussed is TREM2; the disease is neoplasm.